Gilead Sciences, Inc.

Healthcare · Drug Manufacturers - General

Overall research band Above average

Quality Mixed

Valuation Exceptional

Balance sheet Mixed

Market confirmation Exceptional

One-minute company read

What this report can tell you now

What the company does

Gilead Sciences, Inc. is a global biopharmaceutical company headquartered in Foster City, California, focused on discovering, developing, and commercializing innovative medicines for serious diseases. Its main products include therapies for HIV/AIDS such as Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/Eviplera, Stribild, and Atripla; Veklury for COVID-19; treatments for liver diseases like Epclusa, Harvoni, Vosevi, Vemlidy, and Viread; and oncology and cell therapy products including Yescarta, Tecartus, Trodelvy, and Zydelig. Additional specialized medicines include Letairis for pulmonary arterial hypertension, Ranexa for chronic angina, and AmBisome for invasive fungal infections. Gilead serves healthcare providers and patients worldwide and generates revenue primarily through the sale of its pharmaceutical products. The company also collaborates with various partners to advance its therapeutic pipeline.

The current research profile is Mixed Setup, with high valuation support. This is a starting point for investigation, not a forecast or recommendation.

Strongest visible signal

Recent market behavior is the strongest visible confirmation. Check whether it agrees with the underlying business evidence.

What to investigate next

Read the latest filing or company update, check the period behind the metrics, and investigate the dimension with the weakest band above.

Before you draw a conclusion

Read the latest filing or company update.
Check the financial period behind each metric.
Investigate the weakest score band and any missing evidence.

Headline fundamentals

A small set of signals worth checking

ROIC26.8%Model input; read with the evidence status and period context.

Operating margin39.7%Model input; read with the evidence status and period context.

Revenue CAGR · 4 years1.9%Model input; read with the evidence status and period context.

FCF margin32.1%Model input; read with the evidence status and period context.

Go deeper when you need to

Compare the right companies, understand what changed, and monitor the evidence.

Peer contextCompare companies using the appropriate economic neighborhood.

Evidence detailSee exact inputs, source context, and model-aware metrics.

HistoryReview score and research changes over time.

MonitoringKeep the questions, risks, and changes that matter in view.

The public report remains useful on its own. Premium adds depth, history, comparison, and monitoring.